Noma (derived from the Greek word meaning "devouring") represents one of dentistry's most devastating oral conditions, a rapidly progressive gangrenous process affecting soft tissues of the oral cavity and surrounding structures. Also termed cancrum oris (Latin for "mouth cancer," despite its non-neoplastic etiology), noma historically devastated pediatric populations during periods of famine, malnutrition, and poor sanitation. While predominantly eradicated in industrialized nations, noma remains endemic in sub-Saharan African regions, affecting malnourished children with incidence rates ranging from 0.5-24 cases per 1000 children in vulnerable populations. The disease's fulminant progression, causing facial disfigurement and mortality rates reaching 80% when untreated, demands immediate recognition, aggressive nutritional intervention, appropriate antibiotic therapy, and urgent surgical management. Understanding the pathophysiology, clinical manifestations, microbiologic basis, and evidence-based treatment protocols enables dentists to recognize early warning signs and facilitate timely intervention preventing catastrophic progression.

Epidemiology and Risk Factor Profile

Noma predominantly affects children aged 2-16 years, with peak incidence between 3-5 years; rare cases occur in adults and adolescents. Severe malnutrition represents the fundamental predisposing factor; virtually all noma patients demonstrate anthropometric markers of protein-energy malnutrition including stunting, wasting, or both. Nutritional status assessment using mid-upper arm circumference (MUAC) demonstrates that noma typically occurs when MUAC falls below 110 mm in children 1-5 years old (indicating moderate acute malnutrition) or below 100 mm (indicating severe acute malnutrition). Measles infection in the preceding 6-12 months substantially increases noma risk through immunosuppression and oral mucosal damage from measles exanthem. Chronic diarrheal disease preceding noma by weeks to months contributes additional immunosuppression and micronutrient depletion. Socioeconomic deprivation including absolute poverty, poor sanitation, and lack of clean water characterizes virtually all noma cases; the disease almost exclusively affects populations living below absolute poverty thresholds with inadequate healthcare access.

Host immune factors predispose to noma development; immunoglobulin A (IgA) deficiency occurs frequently in noma patients, and more generalized immunoglobulin deficiency states increase disease incidence. Human immunodeficiency virus (HIV) infection substantially increases noma risk in endemic regions; coinfected patients demonstrate accelerated disease progression and increased treatment complexity. Genetic predisposition possibly contributes; certain populations demonstrate higher noma incidence despite similar socioeconomic circumstances, suggesting genetic factors influence susceptibility. Hepatitis B and C infections may increase risk through immune dysfunction. Iron, zinc, vitamin A, and vitamin C deficiency states impair immune function and wound healing, contributing to noma pathogenesis. The intersection of severe malnutrition, infectious disease burden, immunodeficiency, and poor sanitation creates the ideal circumstances for noma development.

Pathophysiologic Mechanisms and Microbiology

Noma pathogenesis involves a complex sequence of mucosal barrier disruption, microbial overgrowth, and subsequent tissue necrosis. Initial oral mucosal damage may result from trauma (dental eruption, tooth eruption, palatal erosion from prolonged bottle feeding), viral infection (herpes simplex virus, measles), or necrotizing ulcerative gingivitis progression. This breach in the mucosal barrier permits opportunistic anaerobic bacteria, predominantly commensal organisms normally held in check by immune function, to proliferate unchecked. Fusobacterium nucleatum and species, Prevotella species (including Prevotella intermedia), Peptostreptococcus species, and various Clostridium species dominate the microflora of noma lesions; these organisms produce powerful proteolytic enzymes including collagenases, hyaluronidases, and tissue-destructive exotoxins.

Bacterial invasion through the compromised mucosa triggers localized inflammatory responses that paradoxically accelerate tissue destruction. Bacterial lipopolysaccharide (LPS) and other pathogen-associated molecular patterns activate toll-like receptors on epithelial cells and innate immune cells, triggering release of tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and other inflammatory mediators. These mediators recruit neutrophils attempting to contain the infection; however, neutrophil elastase and other neutrophil-derived proteases paradoxically amplify tissue destruction. The malnourished host, unable to mount adequate immune responses and deficient in micronutrients essential for wound repair, cannot contain this progressive tissue destruction. The infected area develops a gangrenous appearance as tissue necrosis accelerates, with borders advancing 1-2 mm daily in untreated cases.

The process extends from the oral mucosa through the underlying connective tissues, potentially involving underlying bone (maxilla, mandible) resulting in bony sequestration and exfoliation. The disease maintains anaerobic characteristics; increased venous pressure from edema and inflammation impairs local blood flow, creating an increasingly hypoxic environment favoring obligate anaerobic bacteria. This positive feedback loop—increasing hypoxia promoting anaerobic growth and bacterial virulence factors creating progressive tissue destruction—accounts for the disease's rapid progression if untreated. Without intervention, the gangrenous process may extend beyond the oral cavity into the maxillary or mandibular sinus, through facial soft tissues, and potentially to vital structures including the intracranial contents.

Clinical Staging and Presentation Characteristics

Noma progresses through distinct clinical stages, with early recognition of prodromal symptoms enabling intervention before irreversible tissue destruction occurs. Stage 1 (Pre-noma or Necrotizing Ulcerative Gingivitis stage) presents with gingival inflammation, ulceration, spontaneous bleeding, and foul-smelling breath (halitosis) with characteristic gangrenous odor. Patients experience oral pain, difficulty eating, and constitutional symptoms including fever, malaise, and generalized lymphadenopathy. This stage may persist 2-4 weeks in mild forms; progression to subsequent stages occurs when nutritional status fails to improve or immune dysfunction prevents ulcer resolution.

Stage 2 (Early Noma) demonstrates rapid advancement with development of facial swelling, particularly in the region of the lesion. An erythematous patch appears intraorally, typically on the gingiva adjacent to dental development sites (primary molar eruption areas most frequent). The lesion demonstrates sharp demarcation from surrounding tissue with characteristic appearance of dead tissue with minimal to no bleeding response. Purulent discharge with foul odor increases markedly. Systemic symptoms intensify with fever potentially reaching 39-40°C, marked malaise, and increasing feeding difficulty. Cervical and submandibular lymphadenopathy becomes pronounced.

Stage 3 (Established Noma with Facial Involvement) demonstrates extension beyond the oral cavity to facial soft tissues. An intraoral necrotic area now extends through the facial tissues with visible extra-oral opening ("facial opening"). The facial region demonstrates edema, inflammation, and visible tissue necrosis. A distinct gangrenous smell becomes evident. Fever typically persists; patients develop increasing systemic signs of sepsis. Tissue destruction at this stage frequently involves underlying bone, with bony sequestration becoming evident as nonviable bone becomes isolated.

Stage 4 (Sequelae and Healing) demonstrates transition from active tissue destruction to chronic scarring and contracture. If patient survives and receives appropriate treatment, active necrosis arrests and epithelialization gradually occurs. Massive facial scarring and contracture develops from the gangrenous process and subsequent healing. Tissue loss may severely compromise oronasal anatomy, creating feeding and respiratory difficulties. Psychological morbidity becomes severe; visible facial disfigurement creates substantial social stigma and psychological trauma in surviving patients.

Immediate Management and Antimicrobial Therapy

Recognition of noma or necrotizing ulcerative gingivitis prodromal features demands urgent intervention. Nutritional support represents the cornerstone of noma management; severely malnourished patients require immediate caloric rehabilitation with target daily intake of 150-200 kcal/kg/day. Therapeutic food formulations (ready-to-use therapeutic foods, RUTF) or hospital-based nutritional support provide concentrated calories as carbohydrate, fat, and protein in proportions optimizing recovery. Protein-energy malnutrition reversal typically requires 4-8 weeks of intensive nutritional support; gradual improvement in immune function occurs as nutritional status normalizes. Micronutrient supplementation should address documented deficiencies: vitamin A 200,000 IU daily (two doses 24 hours apart), vitamin C 500 mg twice daily, zinc 10-15 mg daily (elemental zinc), and iron supplementation (15-30 mg elemental iron daily) depending on age and hemoglobin status.

Broad-spectrum antibiotic therapy targeting the anaerobic microflora dominates early noma management. Intravenous clindamycin 10-15 mg/kg/dose three times daily for 7-10 days provides excellent anaerobic coverage including Fusobacterium and Prevotella species with good tissue penetration. Alternative options include intravenous metronidazole 7.5 mg/kg three times daily combined with intravenous ampicillin 25-50 mg/kg three times daily, providing coverage of both anaerobes and gram-positive organisms. For patients in settings lacking intravenous capabilities, intramuscular ceftriaxone 80 mg/kg daily combined with oral metronidazole 7.5-10 mg/kg three times daily provides reasonable alternatives. Duration of antibiotic therapy typically extends 7-14 days depending on clinical response; signs of improvement (decreased odor, reduced purulent drainage, arrest of tissue progression) should become evident by 3-5 days.

Adjunctive topical antimicrobials support systemic antibiotic therapy. Chlorhexidine gluconate 0.12% rinse or mouthwash used 2-3 times daily provides topical antimicrobial activity targeting oral anaerobes. Hydrogen peroxide 3% rinse (1-minute rinses twice daily) provides mechanical cleaning of necrotic tissue. Povidone-iodine topical application should be avoided due to potential systemic iodine absorption in children. Gentle mechanical debridement of obviously necrotic tissue may be performed with blunt curettes or gauze, removing the worst affected tissue; however, aggressive surgical debridement should be deferred until acute sepsis stabilizes with antibiotic therapy and nutritional support, typically after 5-7 days.

Surgical Debridement and Reconstructive Considerations

Once acute infection demonstrates control (typically 5-10 days following treatment initiation), surgical debridement of remaining gangrenous tissue should be performed under general anesthesia. Thorough demarcation distinguishing viable from necrotic tissue must occur before debridement; premature extensive surgery in actively infected areas increases morbidity. The surgical approach employs sharp debridement removing necrotic tissue down to visibly bleeding, healthy tissue. Bone sequestra (nonviable bony fragments) should be removed if readily separable; however, aggressive bony surgery should be avoided during acute management given infection risk. Most authorities recommend staged surgical approach with initial debridement removing most gangrenous tissue, followed by delayed debridement at 5-7 day intervals until all necrotic tissue is removed.

The extent of surgical debridement varies dramatically depending on disease stage at presentation. Early-stage noma identified with limited oral mucosal involvement may require minimal surgical intervention beyond clearing loose necrotic tissue; such cases frequently achieve healing with conservative management. Late-stage presentations with extensive facial involvement and significant bony destruction may require debridement creating substantial facial defects. Some patients require temporary tracheostomy to maintain airway patency during acute management and healing phases. Feeding access frequently requires temporary nasogastric tube placement or, in severe cases, temporary gastrostomy for nutritional support continuation.

Reconstructive surgery should be deferred until acute infection completely resolves, typically 3-6 months or longer after initial presentation. Remaining facial and oral defects frequently prove severe; large facial defects may require staged soft tissue reconstruction using rotational flaps, free tissue transfer, or combinations. Oral mucosal reconstruction permits restoration of oral function and feeding capability. Contracture release becomes necessary in many cases; the gangrenous process and subsequent healing create significant scarring and contracture limiting mouth opening and compromising oral function. Multiple surgical procedures over 12-24 months frequently prove necessary for optimal functional and esthetic restoration.

Systemic Complications and Sepsis Management

Advanced noma carries risk for rapid progression to sepsis and septic shock; patients with untreated advanced disease may deteriorate precipitously. Signs of systemic sepsis include persistent fever exceeding 39-40°C, tachycardia, tachypnea, lethargy or agitation, oliguria, and metabolic acidosis. Septic shock may develop with hypotension, altered mental status, and multi-organ dysfunction. Intensive care management becomes necessary for septic patients; aggressive fluid resuscitation, vasopressor support, and mechanical ventilation may prove necessary. Laboratory assessments should include complete blood count demonstrating leukocytosis, blood cultures to identify resistant organisms, chemistry panel assessing organ function and metabolic derangement, and lactate levels indicating tissue hypoperfusion.

Secondary infections with hospital-acquired pathogens (methicillin-resistant Staphylococcus aureus [MRSA], Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter species) may complicate hospitalization; appropriate surveillance cultures and targeted antibiotic adjustment based on culture results become essential. Osteomyelitis of the maxilla or mandible may develop if bony involvement progresses; imaging with computed tomography demonstrates bony involvement and guides surgical planning. Mediastinitis from extension into the thorax represents a catastrophic complication; recognition through chest imaging and clinical signs (chest pain, dyspnea, septic appearance) demands urgent thoracic surgical consultation and aggressive drainage.

Prevention Strategies and Public Health Intervention

Prevention of noma fundamentally depends upon ameliorating the poverty, malnutrition, poor sanitation, and lack of healthcare characterizing endemic regions. Strengthening nutrition, particularly targeting vulnerable populations (young children, pregnant women, immunocompromised individuals), dramatically reduces noma incidence. Community-based nutrition programs providing supplementary feeding, particularly protein supplementation to young children in endemic regions, demonstrably reduce noma incidence. Vaccination programs preventing measles and other immunosuppressive infections indirectly reduce noma incidence through preserved immune function. Healthcare access improvements enabling early recognition and treatment of necrotizing gingivitis and pre-noma conditions prevent progression to established noma.

Oral health promotion and education in endemic regions improves early disease recognition. Community health workers trained to identify necrotizing ulcerative gingivitis and pre-noma lesions enable earlier intervention at more treatable disease stages. Water, sanitation, and hygiene (WASH) improvements reduce infectious disease burden and support immune function. Public health campaigns addressing poverty and its health consequences represent long-term strategies preventing noma emergence. For populations in endemic regions already affected by active disease burden, rapid referral systems connecting remote villages with surgical centers capable of managing noma become essential for survival and minimization of disfigurement.

Prognosis and Long-Term Outcomes in Survivors

Mortality from untreated noma reaches 80-90% in severe cases; early intervention with nutritional support and appropriate antibiotic therapy reduces mortality to 5-25% depending on disease stage at presentation and healthcare access quality. Early-stage disease with limited mucosal involvement carries substantially better prognosis; mortality in Stage 1-2 disease with appropriate treatment approximates 5-15%. Advanced disease with extensive facial involvement (Stage 3-4) carries higher mortality; even with treatment, mortality reaches 20-40% in some series. Survivors frequently suffer severe morbidity; facial disfigurement, scarring, and contracture create substantial psychological and functional disability. Oral dysfunction from contracture limits mouth opening and may compromise feeding, speech, and dental care access.

Dental sequelae include severe dental malposition from bony destruction, enamel hypomineralization and pitting (amelogenesis imperfecta-like appearance) if noma occurred during tooth development, and increased caries risk from feeding difficulty and oral hygiene compromise. Long-term psychological effects prove significant; disfigured patients frequently experience depression, anxiety, and social isolation from stigma. Integration into society and educational/employment opportunities frequently prove limited by visible disfigurement. The long-term burden of noma-related disability emphasizes the critical importance of prevention through nutrition and basic healthcare access.